| Technical Name | Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine | ||
|---|---|---|---|
| Project Operator | National Health Research Institutes Institute of Biomedical Engineering and Nanomedicine | ||
| Project Host | 陳慧諴 | ||
| Summary | The present invention relates to a method for decreasing the abuse liability and psychotomimetic side effects and enhancing the antidepressant-like effects of ketamine by the combination of ketamine with a methyl glycine derivative. The combination can be applied in the treatment of treatment-resistant depression/bipolar disorders, anxiety disorders and pain. |
||
| Scientific Breakthrough | As NMDA receptor partial agonists, TMG/DMG exhibited antidepressant property and enhance ketamine’s antidepressant effect. However, TMG/DMG decreased the psychotomimetic effect and abuse liability of ketamine. Repeated treatment TMG/DMG with ketamine abolished the persistent psychotypical behavior and memory deficits. A better safety profile of ketamine in combination with TMG/DMG was revealed. |
||
| Industrial Applicability | Combination use of methylglycine derivatives and ketamine can potentially develop formulas to resolve the safety concern of ketamine use in psychiatric disorders. The combination use can reduce the costs and limitation compared to Spravato. It can be applied in the treatment of suicidal ideation, treatment-resistant depression/bipolar disorders, anxiety disorders and pain. |
||
| Keyword | Composition new treatment method antidepressant better safety profile reduced side effect pain relief anxiety disorders reduced abuse liability rapid-onset | ||
- Contact
- Min Hsuan Cheng
- milocheng@nhri.edu.tw
other people also saw
